Calyxha is a private biotech company developing novel small molecule anti-inflammatory drugs. Lead by an experienced team of biotech entrepreneurs and scientists, Calyxha targets multiple inflammatory diseases and is currently in preclinical development.

​

Calyxha's lead product, CAL-4 is being developed as a safe alternative to corticosteroids for asthma and is due to enter the clinic by 2024.